On June 5, 2024, Concor Pharma-B (09966.HK) announced that its wholly-owned subsidiary, Jiangsu Kangning Jerry Biopharmaceutical Co., Ltd. (Kangning Jerry), has entered into a research and cooperation agreement with ArriVent BioPharma, Inc. (which is listed on the NASDAQ Global Market under the stock code:AVBP) (ArriVent).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.